Xin Lang Cai Jing·2026-01-15 01:53Core Viewpoint - The China Securities Regulatory Commission (CSRC) has initiated an investigation into Zhejiang Sunflower Health Technology Co., Ltd. for misleading statements in its restructuring proposal, which has raised market concerns regarding the actual production capacity and business model of the restructuring target [1][3]. Group 1: Investigation and Legal Actions - The Zhejiang Securities Regulatory Bureau has found that the restructuring proposal of Sunflower may contain misleading statements, leading to a formal investigation [1][4]. - Investors who suffered losses due to alleged false statements can seek compensation through legal channels, as per the Supreme People's Court's judicial interpretation regarding false statements [4][5]. - The investigation will ensure the maintenance of order in the mergers and acquisitions market [1]. Group 2: Compensation Eligibility - Investors who purchased Sunflower shares (stock code: 300311) between September 22, 2025, and December 25, 2025, and still held them at the close on December 25, 2025, are eligible to file for compensation [2][4]. - Compensation claims can include losses from investment differences, commissions, and stamp duty losses [4][5]. - Investors must provide specific documentation, including securities account information, stock reconciliation statements from September 1, 2025, to the present, and contact information to support their claims [5].